Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company SOM Biotech S.L.
DescriptionVesicular monoamine transporter 2 (VMAT2; SLC18A2) inhibitor
Molecular Target Vesicular monoamine transporter 2 (VMAT2) (SLC18A2)
Mechanism of ActionVesicular monoamine transporter 2 inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I
Standard IndicationHuntington's disease (HD)
Indication DetailsTreat Huntington's disease (HD)
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today